Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras 26504, Greece.
J Control Release. 2023 Sep;361:212-235. doi: 10.1016/j.jconrel.2023.07.039. Epub 2023 Aug 8.
The characteristics of the primary tumor blood vessels and the tumor microenvironment drive the enhanced permeability and retention (EPR) effect, which confers an advantage towards enhanced delivery of anti-cancer nanomedicine and has shown beneficial effects in preclinical models. Increased vascular permeability is a landmark feature of the tumor vessels and an important driver of the EPR. The main focus of this review is the endothelial regulation of vascular permeability. We discuss current challenges of targeting vascular permeability towards clinical translation and summarize the structural components and mechanisms of endothelial permeability, the principal mediators and signaling players, the targeted approaches that have been used and their outcomes to date. We also critically discuss the effects of the tumor-infiltrating immune cells, their interplay with the tumor vessels and the impact of immune responses on nanomedicine delivery, the impact of anti-angiogenic and tumor-stroma targeting approaches, and desirable nanoparticle design approaches for greater translational benefit.
原发性肿瘤血管的特征和肿瘤微环境驱动增强通透性和保留(EPR)效应,有利于抗癌纳米药物的递释,并在临床前模型中显示出有益效果。血管通透性增加是肿瘤血管的一个标志性特征,也是 EPR 的一个重要驱动因素。本综述的主要重点是内皮细胞对血管通透性的调节。我们讨论了将血管通透性靶向治疗转化为临床应用的当前挑战,并总结了内皮通透性的结构成分和机制、主要介质和信号转导因子、已使用的靶向方法及其迄今为止的结果。我们还批判性地讨论了肿瘤浸润免疫细胞的影响,它们与肿瘤血管的相互作用,以及免疫反应对纳米药物递释的影响,抗血管生成和肿瘤基质靶向方法的影响,以及更有利于转化的理想纳米颗粒设计方法。